1. Home
  2. HONA vs ARGX Comparison

HONA vs ARGX Comparison

Compare HONA & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HONA

Honeywell Aerospace Inc. Common Stock

N/A

Current Price

$203.29

Market Cap

67.5B

Sector

Industrials

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$916.84

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HONA
ARGX
Founded
N/A
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5B
58.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HONA
ARGX
Price
$203.29
$916.84
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
$1,008.56
AVG Volume (30 Days)
3.2M
303.4K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$44.39
Revenue Next Year
N/A
$20.84
P/E Ratio
N/A
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$193.33
$591.32
52 Week High
$266.62
$953.58

Technical Indicators

Market Signals
Indicator
HONA
ARGX
Relative Strength Index (RSI) 29.26 57.16
Support Level $203.00 $886.25
Resistance Level $217.83 $939.08
Average True Range (ATR) 11.79 25.36
MACD -1.77 0.36
Stochastic Oscillator 21.37 77.12

Price Performance

Historical Comparison
HONA
ARGX

About HONA Honeywell Aerospace Inc. Common Stock

Honeywell Aerospace Inc operates as an aerospace and defense supplier of systems and technologies that enable the production, maintenance, and safe operation of aerospace and defense platforms. Its products support original equipment manufacturer (OEM), government, defense prime contractor, and aircraft operator customers across the Commercial Air Transport, Business Aviation, and Defense and Space end markets. The company has three operating segments: Electronic Solutions (ES), Engines & Power Systems (E&PS), and Control Systems (CS ). The majority of revenue is derived from the Electronic Solutions segment, which offers Avionics, Navigation and Sensors, Electromagnetic Defensive Solutions, and Space systems. Geographically, the maximum revenue is generated from the United States.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: